NASDAQ:ETTX - Entasis Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 60.77 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.11
▲ +0.2 (6.87%)

This chart shows the closing price for ETTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Entasis Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETTX

Analyst Price Target is $5.00
▲ +60.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 60.77% upside from the last price of $3.11.

This chart shows the closing price for ETTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Entasis Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2021HC WainwrightReiterated RatingBuy$5.00High
8/29/2021BMO Capital MarketsReiterated RatingBuyLow
8/13/2021HC WainwrightReiterated RatingBuyHigh
11/16/2020Alliance Global PartnersInitiated CoverageBuyLow
9/8/2020Cantor FitzgeraldInitiated CoverageOverweight$5.00Low
8/7/2020HC WainwrightReiterated RatingBuy$5.00Medium
7/13/2020Roth CapitalInitiated CoverageBuy$9.00Medium
6/21/2020CSFBReiterated RatingOutperform$8.00Low
6/21/2020WedbushReiterated RatingOutperform$7.00Low
6/21/2020Credit Suisse GroupReiterated RatingOutperform$8.00Low
5/8/2020BMO Capital MarketsLower Price TargetOutperform$15.00 ➝ $5.00High
4/14/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $5.00High
3/12/2020CSFBLower Price TargetOutperform$18.00 ➝ $14.00Low
3/12/2020Credit Suisse GroupLower Price TargetOutperform$18.00 ➝ $14.00Medium
3/12/2020HC WainwrightReiterated RatingBuyHigh
11/18/2019WedbushReiterated RatingOutperformMedium
8/19/2019HC WainwrightInitiated CoverageBuy$18.00Low
4/2/2019WedbushReiterated RatingOutperform$19.00 ➝ $19.00High
10/24/2018SunTrust BanksInitiated CoverageBuy$20.00High
10/22/2018Credit Suisse GroupInitiated CoverageOutperform$18.00Low
10/22/2018WedbushInitiated CoverageOutperform$19.00Medium
10/22/2018BMO Capital MarketsInitiated CoverageOutperform$18.00Medium
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/20/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Entasis Therapeutics logo
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $3.11
Low: $2.99
High: $3.50

50 Day Range

MA: $2.58
Low: $2.27
High: $3.11

52 Week Range

Now: $3.11
Low: $1.58
High: $3.74

Volume

1,204,386 shs

Average Volume

149,241 shs

Market Capitalization

$147.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Entasis Therapeutics?

The following Wall Street sell-side analysts have issued reports on Entasis Therapeutics in the last twelve months: Alliance Global Partners, BMO Capital Markets, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ETTX.

What is the current price target for Entasis Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Entasis Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 60.8%. HC Wainwright has the highest price target set, predicting ETTX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Entasis Therapeutics in the next year.
View the latest price targets for ETTX.

What is the current consensus analyst rating for Entasis Therapeutics?

Entasis Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETTX will outperform the market and that investors should add to their positions of Entasis Therapeutics.
View the latest ratings for ETTX.

What other companies compete with Entasis Therapeutics?

How do I contact Entasis Therapeutics' investor relations team?

Entasis Therapeutics' physical mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company's listed phone number is (781) 810-0120 and its investor relations email address is [email protected] The official website for Entasis Therapeutics is www.entasistx.com.